Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-12
2010-02-09
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S305000
Reexamination Certificate
active
07659282
ABSTRACT:
Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
REFERENCES:
patent: 3536809 (1970-10-01), Appelzweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4316888 (1982-02-01), Nelson
patent: 4806543 (1989-02-01), Choi
patent: 5034400 (1991-07-01), Olney
patent: 5166207 (1992-11-01), Smith
patent: 5206248 (1993-04-01), Smith
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5350756 (1994-09-01), Smith
patent: 5352683 (1994-10-01), Mayer et al.
patent: 5366980 (1994-11-01), Smith
patent: 5502058 (1996-03-01), Mayer et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5863927 (1999-01-01), Smith et al.
patent: 6207674 (2001-03-01), Smith
patent: 2002/0068718 (2002-06-01), Pierce
patent: 2004/0087479 (2004-05-01), Sosnowski et al.
patent: WO 96 09044 (1996-03-01), None
patent: WO 00/17366 (2000-03-01), None
patent: WO 00/59486 (2000-10-01), None
Gould. 1986, Salt selection for basic drugs. International Journal of Pharmaceutics, vol. 33, pp. 201-217.
Ben Abraham, et al., “Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients”,Clin J Pain, (2002) 18: 282-285.
Bensimon, et al., “A controlled trial of Riluzole in amyotrophic lateral sclerosis”,N Eng J Med. (1994) 330:585-91.
Broly, et al., CA 111: 89742z, 1989.
Broly, et al. “Effect of quinidine on the dextromethorphanO-demethylase activity of microsomal fractions from human liver”,Br J Clin Pharmacol. (1989) 28(1): 29-36.
Broly, et al., CA 112: 210493v, 1990.
Broly, et al., “Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes”,Biochem Pharmacol. (1990) 39:1045-1053.
Brooks, “Personality change after severe head injury”Acta NeurochirurgicaSuppl. (1988) 44: 59-64.
Chase, et al., “Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms”,J Neurol. (2000) 247 Suppl 2:II36-II42.
Cottrell, et al., J. Neurol. Psychopathol., 1926; 7:1-30.
Craviso, et al., “High-affinity dextromethorphan binding sites in guinea pig brain. I. Initial characterization”,Mol Pharmacol., (1983) 23(3):619-628.
Craviso, et al., “High-affinity dextromethorphan binding sites in guinea pig brain. II. Competition experiments”,Mol Pharmacol. (1983) 23(3):629-40.
Dayer, et al. “Dextromethorphan O-demethylation in liver microsomes as a prototype creation to monitor cytochrome P-450 db1 activity”,Clin Pharmacol Ther., (1989) 45(1):34-40.
Desmeules, et al., “Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan”,J Pharmacol Exp Ther., (1999) 288(2): 607-612.
Dickenson, et al., “Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurons following C fibre stimulation”,Neuropharmacology(1987) 26(8): 1235-1238.
Dickenson, et al., “Dextromethorphan and levorphanol on dorsal horn nociceptive neurones in the rat”,Neuropharmacology(1991)30: 1303-1308.
Doble, “The pharmacology and mechanism of action of riluzole”,Neurology(1996) 47(6 Suppl 4):S233-41.
Droll, et al., “Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasions”,Pharmacogenetics(1998) 8(4): 325-333.
Due Nielsen, et al., CA 112: 171691m, 1990.
France, et al., “Analgesic effects of phencyclidine-like drugs in rhesus monkeys,”J Pharmacol Exp Ther., (1989) 250(1): 197-201.
Grass, et al, “N-methyl-D-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat”,Acta Physiol Scand. (1996) 158(3): 269-73.
Heiskanen, et al., “Analgesic effects of dextromethorphan and morphine in patients with chronic pain”,Pain(2002) 96(3): 261-267.
Hoffmann, et al, “Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats”,Neuroreport(1996) 7(3): 838-40.
Inaba, T., et al, “Quinidine: Potent inhibition of sparteine and debrisoquin oxidation in vivo,” Br. J. Clin. Pharmacol. 22: 199-200, 1986.
Jerusalem, et al., “ALS”,Neurology(1996) 47(6 Suppl 4):218S-220S.
Kalin, et al., CA 108: 124860y, 1988.
Kalin et al, “Opiate modulation of separation-induced distress in non-human primates,” Brain Research 440: 285-292, 1988.
Kauppila, et al, “Dextromethorphan potentiates the effect of morphine in rats with peripheral neuropathy,”Neuroreport(1998) 9(6): 1071-4.
Klein, et al., “The effect of prototypic sigma ligands on the binding of [3H] dextromethorphan to guinea pig brain”,Neurosci Lett., (1989) 97(1-2):175-80.
Koyuncuoglu, et al, “The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine”,Int J Clin Pharmacol Ther Toxicol. (1990) 28(4): 147-52.
Kronbach, et al., “High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver”, Anal Biochem. (1987) 162(1):24-32.
Küpfer , A., et al “Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism,”Lancet(1984) 2:517-518,.
Kwiecinski, “Symptomatic treatment and palliative care of ALS”,Neurol Neurochir Pol. (2001) 35:51-9, abstract only.
Largent, et al., “Structural determinants of sigma receptor affinity”,Mol Pharmacol. (1987) 32(6):772-84.
Manning, et al, “Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance,”Pain(1996) 67: 79-88.
Mao, et al, “Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats,”Pain(1996) 67: 361-8.
Musacchio, et al., “Dextromethorphan binding sites in the guinea pig brain”,Cell Mol Neurobiol., (1988) 8(2):149-56.
Musacchio, et al., “High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions”,J Pharmacol Exp Ther., (1988) 247(2):424-31.
Otton, et al., “In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver”,Drug Metab Dispos. (1988) 16(1):15-7.
Otton, et al., “Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes”,J Pharmacol Exp Ther., (1988) 247(1):242-7.
Parvivzi, et al., “Pathological laughter and crying—A link to the cerebellum”,Brain, 2001;124:1708-19.
Physician's Desk Reference, 44th Edition, 1990, pp. 670-671 (Medical Economics Company, 1990).
Plesan, et al, “Comparison of ketamine and dextromethorphan in potentiating the antinociceptive effect of morphine in rats,”Anesth Analg. (1998) 86(4): 825-9,.
Ramachander, et al., “Determination of dextrorphan in plasma and evaluation of bioavailability of dextromethorphan hydrobromide in humans”,J Pharm Sci. (1977) 66(7):1047-8.
Ross, et al., “Pathological display of affect in patients with depression and right frontal brain damage. An alternative mechanism”,J Nerv Ment Dis. (1987) 175(3):165-72.
Sang, “NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials”,Pain Symptom Manage. (2000) 19(1 Suppl): S21-25.
Shaw et al., Brain Sciences in Psychiatry, London: Butterworth, 1982 (Contents pages only) 3 pages.
Smith et al., “The treatment of affec
Berg James
Pope Laura E.
Smith Richard A.
Yakatan Gerald
Avanir Pharmaceuticals, Inc.
McMillian Kara R
Padmanabhan Sreeni
Townsend and Townsend / and Crew LLP
LandOfFree
Pharmaceutical compositions comprising dextromethorphan and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising dextromethorphan and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising dextromethorphan and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160494